DeCure for Chondrodysplasia-pseudohermaphroditism syndrome
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for chondrodysplasia-pseudohermaphroditism syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleChondrodysplasia-pseudohermaphroditism syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for chondrodysplasia-pseudohermaphroditism syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
hedgehog acyltransferase (HHAT) — HHAT is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet hemdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7MHY · 2.7 Å · ligand PROTOPORPHYRIN IX CONTAINING FE (HEM). Experimental structure, not a prediction.
What the evidence adds up to
The 2003 review notes that chondrodysplasia is a genetically and clinically heterogeneous group of skeletal disorders, but it offers no treatment data. The 2024 study describes a nanoplatform (MMOS-Ica@HA) tested in vitro on bone marrow stromal cells and in vivo in zebrafish embryos. In those experiments, the nanoplatform promoted chondrogenic differentiation via the Smad5/HIF-1α signalling pathway and improved cartilage formation. No human subjects were involved; no survival or response rates are reported. The 2007 case report describes a 22-week fetus with short-limbed chondrodysplasia diagnosed after the mother had taken a trado-herbal drug for subfertility in three consecutive pregnancies. That report does not test any intervention.
The 2024 nanoplatform results are limited to cell and zebrafish models. There is no evidence that any drug or material has been tested in humans for chondrodysplasia-pseudohermaphroditism syndrome. The 2007 case suggests a possible environmental or herbal exposure association, but no controlled data confirm causation or treatment effect.
What is missing: any human clinical trial for this syndrome, any validated animal model that recapitulates the pseudohermaphroditism component, and any funding or trial design that would test a drug in patients. Patient stratification by genetic subtype is also absent from the available literature.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Fetal and Pediatric Pathology · 2003 · 6 citations
The evolving definition of a chondrodysplasia?
AbstractMost individuals who deal with chondrodysplasias would agree that this term refers collectively to a genetically and clinically heterogeneous group of disorders of skeletal development and growth. But they might not agree on what constitutes a specific chondrodysplasia. Indeed, the way in which a specific chondrodysplasia is defined has evolved substantially over the past several decades. David Rimoin, to whom this special issue is dedicated, has played a vital role in this evolution.
International Journal of Nanomedicine · 2024 · 5 citations · open access
Empowering Cartilage Restructuring with Biodegradable Magnesium Doped-Silicon Based-Nanoplatforms: Sustained Delivery and Enhanced Differentiation Potential
AbstractBackground: Cartilage-related diseases, such as hypoplastic chondrodysplasia a rare genetic disorder that affects newborns, causing abnormal cartilage development and restricted skeletal growth. However, the development of effective treatment strategies for chondrodysplasia still faces significant challenges due to limitations in the controlled drug delivery, biocompatibility, and biodegradability of nanomedicines. Methods: ions through the "dissolution-regrowth" method, resulting in MMOS. Ica was effectively loaded into the MMOS channels, and HA was anchored on the surface of MOS to obtain MMOS-Ica@HA nanoplatforms. Additionally, in vitro cell experiments and in vivo zebrafish embryo models were used to evaluate the effect of the nanoplatforms on cartilage differentiation or formation and the efficiency of treating chondrodysplasia. Results: A series of characterization tests including TEM, SEM, DLS, XPS, EDX, and BET analysis validate the successful preparation of MOS-Ica@HA nanoplatforms. The prepared nanoplatforms show excellent dispersion and controllable drug release behavior. The cytotoxicity evaluation reveals the good biocompatibility of MOS-Ica@HA due to the sustained and controllable release of Ica. Importantly, the presence of Ica and Mg component in MOS-Ica@HA significantly promote chondrogenic differentiation of BMSCs via the Smad5/HIF-1α signaling pathway. In vitro and in vivo experiments confirmed that the nanoplatforms improved chondrodysplasia by promoting cartilage differentiation and formation. Conclusion: The findings suggest the potential application of the developed biodegradable MMOS-Ica@HA nanoplatforms with acceptable drug loading capacity and controlled drug release in chondrodysplasia treatment, which indicates a promising approach for the treatment of chondrodysplasia.
Annals of African Medicine · 2007 · 2 citations · open access
Foetal chondrodysplasia: Intrauterine diagnosis
AbstractChondrodysplasias are rare occurrence. We present a case of short-limbed chondrodyplasia diagnosed in a 22 week fetus of a 28 year old. She was para 4(+0) with two children alive. She had similar occurrences in her last two pregnancies. The index pregnancy and the last two eventful pregnancies were preceded with ingestion of trado-herbal drug to treat subfertility.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
